1402166-71-5 Usage
Uses
Used in Organic Synthesis:
1-(2-Cyanophenyl)pyrazole-4-boronic acid, pinacol ester is used as a synthetic intermediate for the creation of complex organic molecules. Its boronic acid functionality allows for the formation of stable covalent bonds with a range of nucleophilic species, which is crucial in the assembly of pharmaceutically relevant compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(2-Cyanophenyl)pyrazole-4-boronic acid, pinacol ester is used as a key building block in the development of new drugs. Its ability to engage in stable bonding with various molecular entities makes it a valuable asset in the design and synthesis of potential therapeutic agents.
Used in Agrochemical Development:
1-(2-Cyanophenyl)pyrazole-4-boronic acid, pinacol ester is employed as a component in the synthesis of agrochemicals, where its reactivity and stability are leveraged to produce compounds with pesticidal or herbicidal properties, contributing to crop protection and yield enhancement.
Used in Material Science:
In the field of material science, 1-(2-Cyanophenyl)pyrazole-4-boronic acid, pinacol ester is used as a precursor for the development of novel materials with specific properties. Its unique chemical structure can be integrated into the design of materials with tailored characteristics for applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1402166-71-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,2,1,6 and 6 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1402166-71:
(9*1)+(8*4)+(7*0)+(6*2)+(5*1)+(4*6)+(3*6)+(2*7)+(1*1)=115
115 % 10 = 5
So 1402166-71-5 is a valid CAS Registry Number.
1402166-71-5Relevant articles and documents
PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF
-
Paragraph 0292-0296; 0171-0172; 0322-0327, (2020/05/14)
Compounds having activity as chemotherapeutic agents are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1a, R1b, R1c, R1d, L, and are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods for treating cancer (e.g., hematological cancers) are also provided.
THERAPEUTIC COMPOUNDS
-
Paragraph 0646; 0647, (2018/11/21)
The present embodiments relate to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition
